Headline–confidence gap
Headline confirmed
Management confidence reinforces the reported beat.
ELV · Q2 2026
Elevance Health, Inc.
45EarnIQ signal
↗
Confidence rising
Mild quarter-over-quarter shiftSolid second-quarter beat and raised full-year guidance reinforce confidence in long-term earnings growth.
- ✓Guidance was raised, with high specificity.
- ✓Management tone registered as confident (80/100).
- ✓EarnIQ detected 0 potential management deflections.
EPS: reported vs expected+18.9%$7.45 vs $6.27
Revenue: reported vs expected—— vs —
Guidance specificityHighRaised
Market expectations supplied by Finnhub · Reported vs consensus estimate
We are raising our 2026 adjusted EPS guidance to at least $27.00 and accelerating targeted investments in the capabilities that matter most.
Premium intelligence
The evidence behind the signal
Management language
Why confidence moved
“Our second quarter results exceeded our outlook, supported by disciplined execution and improved operating performance across our diversified portfolio.”
“We are raising our 2026 adjusted EPS guidance to at least $27.00 and accelerating targeted investments in the capabilities that matter most”
“These actions will strengthen how we operate, improve consistency over time, and reinforce our confidence in returning to at least 12% adjusted EPS growth in 2027 off our 2026 earnings baseline.”
Guidance specificity
80/100
High specificity
FY 2026 diluted EPS guidance raised to at least $20.10, adjusted diluted EPS guidance raised to at least $27.00, and operating cash flow guidance raised to at least $6.0 billion.
Pressure point
Elevated medical cost trends in
0 potential deflections detected in management communication.
Narrative break
What changed
Accelerating targeted investments in capabilities that lower healthcare costs, simplify member and provider experience, and strengthen Carelon's integrated solutions.
Q&A evidence
Management responses
No material Q&A deflections were detected.
Key positives
- Adjusted diluted EPS of $7.45 supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit.
- Full-year 2026 adjusted EPS guidance raised to at least $27.00 and operating cash flow guidance raised to at least $6.0 billion.
- Carelon reportable segment operating revenue grew 6 percent year over year to $19.2 billion, driven by scaling of risk-based solutions and specialty pharmacy profitability.
Key risks
- Elevated medical cost trends in Government businesses leading to an 80 basis point increase in the benefit expense ratio year over year.
- Anticipated declines in Medicare Advantage, Medicaid, and Employer Group risk membership driving sequential and year-over-year membership contractions.
- Higher operating expenses resulting from targeted investments in workforce and long-term operating model capabilities.
Topic velocity
Language versus prior quarter
M&ANew
CostNew
ChinaNew
MarginNew
RecordNew
iPhoneNew
Signal composition
What drove the EarnIQ score
Tone+17
Eps Beat+0
Guidance+12
New Signal+8
Miss Penalty+0
Qoq Improvement+8
Deflection Penalty+0